In a filing, Relay Therapeutics Inc revealed its President, R&D Bergstrom Donald A unloaded Company’s shares for reported $30636.0 on Jan 29 ’24. In the deal valued at $9.64 per share,3,178 shares were sold. As a result of this transaction, Bergstrom Donald A now holds 530,878 shares worth roughly $4.02 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Catinazzo Thomas sold 2,005 shares, generating $19,328 in total proceeds. Upon selling the shares at $9.64, the Chief Financial Officer now owns 341,846 shares.
Before that, Adams Brian sold 1,929 shares. Relay Therapeutics Inc shares valued at $18,596 were divested by the Chief Legal Officer at a price of $9.64 per share. As a result of the transaction, Adams Brian now holds 327,738 shares, worth roughly $2.48 million.
Jefferies upgraded its Relay Therapeutics Inc [RLAY] rating to a Hold from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Raymond James’s analysts, who increased its forecast for the stock in mid April from “an Outperform” to “a Strong buy”. Raymond James began covering RLAY with “an Outperform” recommendation on April 13, 2023. Oppenheimer started covering the stock on February 03, 2023. It rated RLAY as “an Outperform”.
Price Performance Review of RLAY
On Tuesday, Relay Therapeutics Inc [NASDAQ:RLAY] saw its stock jump 0.53% to $7.57. Over the last five days, the stock has lost -2.82%. Relay Therapeutics Inc shares have fallen nearly -31.24% since the year began. Nevertheless, the stocks have fallen -50.56% over the past one year. While a 52-week high of $19.23 was reached on 01/08/24, a 52-week low of $5.95 was recorded on 03/18/24. SMA at 50 days reached $9.48, while 200 days put it at $9.85. A total of 1.74 million shares were traded, compared to the trading of 0.83 million shares in the previous session.
Levels Of Support And Resistance For RLAY Stock
The 24-hour chart illustrates a support level at 7.44, which if violated will result in even more drops to 7.30. On the upside, there is a resistance level at 7.77. A further resistance level may holdings at 7.96. The Relative Strength Index (RSI) on the 14-day chart is 31.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.85, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.72%. Stochastics %K at 7.14% indicates the stock is a buying.
How much short interest is there in Relay Therapeutics Inc?
A steep rise in short interest was recorded in Relay Therapeutics Inc stocks on Feb 29, 2024, growing by 1.55 million shares to a total of 11.0 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 9.45 million shares. There was a rise of 14.09%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 10.79% of the overall stock float, the days-to-cover ratio (short ratio) rose to 9.58.
The most recent change occurred on September 30, 2022 when Barclays began covering the stock and recommended ‘”an Equal weight”‘ rating along with a $23 price target.
